Combined Therapy for Acne Scars

Not Applicable

• Conditions: Atrophic Acne Scar

• Registration Number: NCT05105334
• Lead Sponsor: Goldman, Butterwick, Fitzpatrick and Groff

Brief Summary

Compare the effectiveness of nonablative fractional resurfacing to radiofrequency micrnoeedling for facial acne scars in all skin types

Detailed Description

Quantify and compare the effectiveness of nonablative fractional laser (Fraxel re:store, Solta Medical, Bothell, WA) alone to nonablative fractional laser alternating with microneedling with radiofrequency (Intracel, Perigee Medical, Redwood City, CA) for the treatment of atrophic, facial acne scars in all skin types.

Study Timeline

• Status Verified: 2021-10
• Study First Submitted: 2021-10-22
• Study First Submitted QC: 2021-11-02
• Last Update Submitted: 2021-11-02
• Study First Posted: 2021-11-03
• Study Start: 2021-11-08
• Last Update Posted: 2021-11-10
• Primary Completion: 2022-05-08
• Study Completion: 2022-07-08

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Change in atrophic acne scar	3 months after final treatment	The primary study endpoint will be clinical efficacy defined as change in atrophic acne scarring based on the ECCA grading scale and a 1-10 percentile scale.

Secondary Outcome Measures

Name	Time	Method
Adverse events	3 months after final treatment	To be recorded by treating physician after treatment.
Subject comfort level	To be done right after treatments	During each treatment visit patients will be asked to grade pain of treatment on a pain visual analog scale.
Subject satisfaction	3 months after final treatment	Subjects will rate satisfaction on a 1-5 scale.
Subjective change	3 months after final treatment	Subjects will rate their perceived global change in acne scarring based on the subjected assessed global improvement scale.